Funder: Pfizer Inc.
Due Dates: April 23, 2026 (Submission deadline, full application)
Funding Amounts: Up to EUR 40,000 per project | Total available: EUR 140,000 | Project duration: up to 18 months
Summary: Funds quality improvement projects to enhance non-pharmacological management of adverse events and quality of life for ALK-positive NSCLC patients treated with ALK TKIs in Spain.
Key Information: Only organizations in Spain are eligible; late applications will not be reviewed.